Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TYMS | P04818 | 2/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180945 | 0.92 | POLB (0.55) | POLBTYMS | |
| SCHEMBL502418 | 0.92 | POLB (0.55) | POLBTYMS | |
| SCHEMBL9900767 | 0.92 | POLB (0.55) | POLBTYMS | |
| SCHEMBL13224513 | 0.90 | POLB (0.53) | POLBTYMSNT5EDTYMK | |
| SCHEMBL13899894 | 0.90 | POLB (0.53) | POLBTYMSNT5EDTYMK | |
| SCHEMBL19681270 | 0.89 | POLB (0.52) | POLBTYMSNT5EDTYMK | |
| SCHEMBL16416278 | 0.89 | POLB (0.52) | POLBTYMSNT5EDTYMK | |
| SCHEMBL14661236 | 0.88 | POLB (0.56) | POLBDTYMK | |
| SCHEMBL14661232 | 0.88 | POLB (0.56) | POLBDTYMK | |
| SCHEMBL224861 | 0.86 | POLG (0.55) | POLBDTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220145303-A1 | FRAGILE X MENTAL RETARDATION PROTEIN INTERFERING OLIGONUCLEOTIDES AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2022-05-12 | — | — | US | claimed |
| EP-3931324-A1 | FRAGILE X MENTAL RETARDATION PROTEIN INTERFERING OLIGONUCLEOTIDES AND METHODS OF USING SAME | Nogra Pharma Limited (IE) | 2022-01-05 | — | — | EP | claimed |
| EP-4689108-A1 | SMAD7 INHIBITORY ANTISENSE OLIGONUCLEOTIDES (ASO) FOR TREATING POUCHITIS AND METHODS OF USING THE SAME | Nogra Pharma Limited (IE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025129098-A1 | TYROSINASE-BASED CONJUGATE COMPOSITIONS AND METHODS OF USE | CATENA BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025059190-A2 | POLYPEPTIDE CONJUGATION COMPOSITIONS AND METHODS OF USE | CATENA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024200594-A1 | SMAD7 INHIBITORY ANTISENSE OLIGONUCLEOTIDES (ASO) FOR TREATING POUCHITIS AND METHODS OF USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2024-10-03 | — | — | WO | disclosed |
| US-20230212582-A1 | COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDES (ASO) AND METHODS OF USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2023-07-06 | — | — | US | disclosed |
| EP-4139459-A2 | COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDES (ASO) AND METHODS OF USING THE SAME | Nogra Pharma Limited (IE) | 2023-03-01 | — | — | EP | disclosed |
| US-20230002770-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2023-01-05 | — | — | US | disclosed |
| CN-115552005-A | Compositions of SMAD7 antisense oligonucleotides (ASOs) and methods of use thereof | 诺格拉制药有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3237018-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | Celgene Alpine Investment Company II, LLC (BM) | 2017-11-01 | — | — | EP | disclosed |
| US-20170247695-A1 | ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES | NOGRA PHARMA LIMITED (IE) | 2017-08-31 | — | — | US | disclosed |
| EP-3207135-A2 | ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES | Celgene Alpine Investment Company II, LLC (BM) | 2017-08-23 | — | — | EP | disclosed |
| WO-2016105516-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-2970419-A1 | METHODS OF TREATING COLORECTAL CANCER | Nogra Pharma Limited (IE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150315573-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | UNIVERSITY OF MIAMI (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015011694-A2 | ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20140271860-A1 | Methods of Treating Colorectal Cancer | NOGRA PHARMA LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140333-A1 | METHODS OF TREATING COLORECTAL CANCER | NOGRA PHARMA LIMITED (IE) | 2014-09-18 | — | — | WO | disclosed |